[Market Focus] FutureChem Rises on Domestic Phase 3 Approval for Prostate Cancer Treatment "FC705"

FutureChem is showing strong performance. This appears to be influenced by the news that the company has received approval from the Ministry of Food and Drug Safety for its domestic Phase 3 clinical trial plan (IND) for the prostate cancer treatment "FC705."

As of 9:14 a.m. on September 5, FutureChem was trading at 23,100 won, up 350 won (1.54%) from the previous trading day.

This Phase 3 clinical trial by FutureChem will target patients with metastatic castration-resistant prostate cancer (mCRPC).

The randomized clinical trial will compare a group receiving only best supportive care (BSC) and standard of care (SoC) with a group receiving a combination of FC705 and these therapies. The plan is to enroll a total of 114 patients at eight medical institutions in the Seoul metropolitan area, including Seoul St. Mary's Hospital.

In the previously conducted Phase 2 trial, FC705 showed the highest rate of PSA reduction by 50% or more and the highest objective response rate (ORR) on imaging compared to other radiopharmaceuticals with the same mechanism of action. In addition, the ongoing Phase 2a trial in the United States has completed enrollment of 20 participants. To date, a total of 136 patients in Korea and the United States have received FC705 either as part of clinical trials or for therapeutic use.